Ozempic’s maker wants the US government to ban cheaper versions of the high-priced $969 injection weight-loss drug – claims the formula is ‘too complex’ to copy safely

What is Novo Nordisk really asking for

Novo Nordisk is asking the FDA to crack down on unapproved, cheaper versions of weight loss drugs. But in the U.S. health care system, compounding pharmacies have long filled supply gaps for essential medications, including cancer treatments like cisplatin.

Often operating as nonprofits, these pharmacies provide more affordable alternatives when branded drugs are unavailable or too expensive. Compounded medications differ mainly in that they lack FDA approval and don’t undergo the same rigorous testing required for branded drugs.

“These drugs are inherently complex to compound safely, and the risks they pose to patient safety far outweigh any benefits,” Novo Nordisk wrote in a statement.

For some patients, however, compounded versions are the only affordable option. With high drug prices and insurance plans often not covering weight-loss treatments, many turn to compounded alternatives.

Discover how a simple decision today could lead to an extra $1.3 million in retirement

Learn how you can set yourself up for a more prosperous future by exploring why so many people who work with financial advisors retire with more wealth.

Discover the full story and see how you could be on the path to an extra $1.3 million in retirement.

Read More

Prioritizing health or protecting profits?

As Novo Nordisk intensifies its efforts to halt the compounding, questions arise about the true motivation behind its push. While the company says patient safety is its primary concern, critics argue the move may be more about protecting profits.

For Jennie Smith, a seamstress in Ohio, Wegovy’s $1,000 monthly price tag made it inaccessible. After researching, she found a compounded version through an online pharmacy, paying just $300 a month instead. While the key ingredient remains the same, this compounded version was produced by a pharmacy, not a pharmaceutical giant like Novo Nordisk.

Scott Brunner, CEO of the Alliance of Pharmacy Compounding, questioned why it took Novo Nordisk two and a half years to raise concerns about compounded versions.

“Novo Nordisk is so deeply concerned about patient safety that it’s taken them a whopping two-and-a-half years while their drug has been in shortage to conclude that the semaglutide API is so demonstrably difficult for compounding pharmacies to prepare that FDA now needs to place it off-limits for compounding?” Brunner wrote in a statement.

With the FDA’s upcoming decision, the accessibility of affordable alternatives hangs in the balance, potentially reshaping the future of weight-loss treatments and patient options.